The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study
Abstract
68Ga-PSMA PET/CT scanning has been shown to be more sensitive than conventional imaging techniques in patients with prostate cancer. This prospective Australian multicenter study assessed whether 68Ga-PSMA PET/CT imaging affects management intent in patients with primary or recurrent prostate cancer. Methods: Before undertaking 68Ga-PSMA PET imaging, referring medical specialists completed a questionnaire detailing relevant demographic and clinical data as well as their proposed management plan. A separate follow-up questionnaire was completed after the 68Ga-PSMA PET/CT scan results were available to determine whether the management plan would change. Results: A total of 431 patients with prostate cancer from 4 Australian centers had pre– and post–68Ga-PSMA management plans completed. Scans were obtained for primary staging of intermediate- and high-risk disease in 25% of patients and for restaging/biochemical recurrence in 75% of patients. Overall, 68Ga-PSMA PET/CT scanning led to a change in planned management in 51% of patients. The impact was greater in the group of patients with biochemical failure after definitive surgery or radiation treatment (62% change in management intent) than in patients undergoing primary staging (21% change). Imaging with 68Ga-PSMA PET/CT revealed unsuspected disease in the prostate bed in 27% of patients, locoregional lymph nodes in 39%, and distant metastatic disease in 16%. Conclusion:68Ga-PSMA PET/CT scans detect previously unsuspected disease and may influence planned clinical management in a high proportion of patients with prostate cancer. The impact was greater in patients with biochemical recurrence. These results demonstrate the potential clinical value of 68Ga-PSMA PET/CT in management of prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eiber, M., Maurer, T., Souvatzoglou, M., Beer, A. J., Ruffani, A., Haller, B., Graner, F.-P., Kübler, H., Haberhorn, U., Eisenhut, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154153 · Cited by 994
Afshar-Oromieh, A., Avtzi, E., Giesel, F. L., Holland-Letz, T., Linhart, H. G., Eder, M., Eisenhut, M., Boxler, S., Hadaschik, B. A., Kratochwil, C., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2949-6 · Cited by 964
Hövels, A. M., Heesakkers, R. A. M., Adang, E. M., Jager, G. J., Strum, S., Hoogeveen, Y. L., Severens, J. L., & Barentsz, J. O. (2008) · Clinical Radiology · doi:10.1016/j.crad.2007.05.022 · Cited by 954
Afshar-Oromieh, A., Zechmann, C. M., Malcher, A., Eder, M., Eisenhut, M., Linhart, H. G., Holland-Letz, T., Hadaschik, B. A., Giesel, F. L., Debus, J., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2525-5 · Cited by 921
Morigi, J. J., Stricker, P. D., van Leeuwen, P. J., Tang, R., Ho, B., Nguyen, Q., Hruby, G., Fogarty, G., Jagavkar, R., Kneebone, A., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.160382 · Cited by 571
Self-citationvan Leeuwen, P. J., Stricker, P., Hruby, G., Kneebone, A., Ting, F., Thompson, B., Nguyen, Q., Ho, B., & Emmett, L. (2016) · BJU International · doi:10.1111/bju.13397 · Cited by 256
Self-citationProstate-specific Membrane Antigen–radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer
Maurer, T., Weirich, G., Schottelius, M., Weineisen, M., Frisch, B., Okur, A., Kübler, H., Thalgott, M., Navab, N., Schwaiger, M., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.04.034 · Cited by 233
68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
Rauscher, I., Maurer, T., Fendler, W. P., Sommer, W. H., Schwaiger, M., & Eiber, M. (2016) · Cancer Imaging · doi:10.1186/s40644-016-0072-6 · Cited by 208
Beresford, M. J., Gillatt, D., Benson, R. J., & Ajithkumar, T. (2010) · Clinical Oncology · doi:10.1016/j.clon.2009.10.015 · Cited by 170
Albisinni, S., Artigas, C., Aoun, F. Y., Biaou, I., Grosman, J., Gil, T., Hawaux, E., Limani, K., Otte, F.-X., Peltier, A., et al. (2016) · British Journal of Urology · doi:10.1111/bju.13739 · Cited by 113
Cited by
Lindström, E., Velikyan, I., Regula, N., Alhuseinalkhudhur, A., Sundin, A., Sörensen, J., & Lubberink, M. (2019) · Theranostics · doi:10.7150/thno.31970 · Cited by 32
Metadata
- Authors
- Roach, P. J., Francis, R., Emmett, L., Hsiao, E., Kneebone, A., Hruby, G., Eade, T., Nguyen, Q. A., Thompson, B. D., Cusick, T., McCarthy, M., Tang, C., Ho, B., Stricker, P. D., & Scott, A. M.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2017-06-23
- Volume
- 59
- Issue
- 1
- Pages
- 82-88
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2673309218
- Cited by
- 367
- References
- 10
- FWCI
- 31.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. https://app.cochat.ai/papers/10.2967/jnumed.117.197160
- The paper
- Roach, P. J., Francis, R., Emmett, L., Hsiao, E., Kneebone, A., Hruby, G., Eade, T., Nguyen, Q. A., Thompson, B. D., Cusick, T., McCarthy, M., Tang, C., Ho, B., Stricker, P. D., & Scott, A. M. (2018). The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.117.197160
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
